Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
#What Is The Projected Market Size Of The Rare Disease Clinical Trials Market By 2029?
The rare disease clinical trials market has experienced rapid expansion in recent years. It is forecast to grow from $12.06 billion in 2024 to $13.30 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.3%. This historical market growth can be attributed to several factors: increasing awareness of genetic disorders among healthcare providers, a rising demand for specialized patient monitoring during trials, the advancement of personalized medicine approaches, the growing adoption of patient-centric trial methodologies, and an increasing need for global multi-center clinical studies.
The rare disease clinical trials market is projected for significant expansion in the coming years, with its size anticipated to reach $19.45 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.0%. This projected growth is attributed to several factors, including an increase in rare disease therapies progressing into clinical trials, greater regulatory support for orphan drug approvals, the development of more disease-specific patient registries and databases, a rise in cross-border clinical trials and multi-center studies, and enhanced funding initiatives for rare disease research infrastructure. Major trends expected during this forecast period include the advanced utilization of decentralized trial models, innovative strategies for patient recruitment, the integration of real-world evidence into trial designs, the continued development of precision medicine approaches, and a growing adoption of digital health technologies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28311&type=smp
Which Industry Drivers Are Expected To Accelerate The Rare Disease Clinical Trials Market From 2025 To 2029?
The emergence of personalized medicine is anticipated to propel the expansion of the rare disease clinical trials market going forward. Personalized medicine involves customizing medical treatment to the distinct characteristics of each patient, including their genetics, lifestyle, and environment. The rise in personalized medicine is a result of improved treatment outcomes, as it tailors therapies to individual patient profiles for greater effectiveness and safety. Rare disease clinical trials contribute to personalized medicine by generating patient-specific insights that inform the development of targeted therapies uniquely designed for each individual’s genetic and molecular profile. For instance, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, indicated that the Food and Drug Administration (FDA) reported personalized medicines accounted for 34% of approvals in 2022, which subsequently increased to 38% in 2023. Consequently, the expansion of personalized medicine is a key driver for the growth of the rare disease clinical trials market.
What Are The Emerging Segments Gaining Attention In The Rare Disease Clinical Trials Market?
The rare disease clinical trials market covered in this report is segmented as
1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Therapeutic Area: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Disease, Genetic Disorders, Autoimmune And Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas
3) By Study Design: Interventional, Observational, Expanded Access
4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Research Institutes, Other End-Users
Subsegments:
1) By Phase I: First In Human Trials, Dose Escalation Studies, Safety And Tolerability Studies
2) By Phase II: Proof Of Concept Studies, Dose Response Studies, Efficacy And Safety Studies
3) By Phase III: Randomized Controlled Trials, Comparative Effectiveness Studies, Large Scale Multicenter Trials
4) By Phase IV: Post Marketing Surveillance, Long Term Safety Studies, Real World Evidence Studies
What Are The Latest Industry Trends Transforming The Rare Disease Clinical Trials Market?
Major companies in the rare disease clinical trials market are focusing on implementing innovations, including adopting a client-focused strategy to deliver personalized trial designs, enhancing patient engagement, and accelerating the development of targeted therapies for rare conditions. This client-focused strategy involves prioritizing the needs, objectives, and preferences of biotech and pharmaceutical clients to provide customized and effective clinical trial solutions. For example, in March 2025, Evestia Clinical Limited, a US-based pharmaceutical research company, was launched as the new brand identity for EMAS Pharma. This rebranding represents a strategic move aimed at accelerating the company’s global expansion. Evestia Clinical Limited is committed to expediting the development of therapies for rare diseases by offering expert-led, personalized clinical trial solutions tailored to the unique challenges of these conditions, with this focus being a core part of its brand identity and service offering.
Who Are The Top Performing Companies In The Rare Disease Clinical Trials Market In Recent Years?
Major companies operating in the rare disease clinical trials market are F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, IQVIA Holdings Inc., Laboratory Corporation of America Holdings, ICON plc, Moderna Inc., Charles River Laboratories International Inc., Parexel International Corporation, Revvity Inc., Sarepta Therapeutics Inc., TFS HealthScience, Inventiva S.A., Tonix Pharmaceuticals Holding Corp., SpringWorks Therapeutics Inc., OrphAI Therapeutics Inc., BBCR Consulting LLC, and Credevo Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/rare-disease-clinical-trials-global-market-report
What Regional Growth Trends Are Shaping The Rare Disease Clinical Trials Market Outlook?
North America was the largest region in the rare disease clinical trials market in 2024. The regions covered in rare disease clinical trials report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Rare Disease Clinical Trials Market Report:
https://www.thebusinessresearchcompany.com/customise?id=28311&type=smp
Browse Through More Reports Similar to the Global Rare Disease Clinical Trials Market 2025, By The Business Research Company
Rare Diseases Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report
Rare Disease Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report
Rare Inflammatory Disease Treatment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model